As of 2025-07-13, the Intrinsic Value of Viracta Therapeutics Inc (VIRX) is -26.09 USD. This VIRX valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Viracta Therapeutics Inc is -33,634.19%.
Based on its market price of 0.08 USD and our intrinsic valuation, Viracta Therapeutics Inc (VIRX) is overvalued by 33,634.19%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -26.09 - -26.09 | -26.09 | -33,634.19% |
| P/E | (70.34) - (98.51) | (72.53) | -93325.0% |
| DDM - Stable | (4.94) - (16.50) | (10.72) | -13879.6% |
| DDM - Multi | (3.30) - (10.52) | (5.15) | -6718.0% |
| Market Cap (mil) | 0.65 |
| Beta | -1.20 |
| Outstanding shares (mil) | 8.30 |
| Enterprise Value (mil) | 4.43 |
| Market risk premium | 4.60% |
| Cost of Equity | 55.17% |
| Cost of Debt | 5.00% |
| WACC | 4.95% |